|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L04AC21
|
|
gptkbp:brand
|
gptkb:Skyrizi
|
|
gptkbp:CASNumber
|
1610353-39-2
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
gptkb:AbbVie
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
risankizumab
|
|
gptkbp:indication
|
moderate to severe Crohn's disease
active psoriatic arthritis
moderate to severe plaque psoriasis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:p19_subunit_of_IL-23
IgG1 monoclonal antibody
|
|
gptkbp:mechanismOfAction
|
IL-23 inhibitor
|
|
gptkbp:pregnancyCategory
|
not assigned (US)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
fatigue
headache
injection site reactions
upper respiratory tract infection
|
|
gptkbp:target
|
gptkb:interleukin-23
|
|
gptkbp:UNII
|
0QX6XJN02F
|
|
gptkbp:usedFor
|
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
plaque psoriasis
|
|
gptkbp:bfsParent
|
gptkb:Skyrizi
|
|
gptkbp:bfsLayer
|
7
|